Chimeric Therapeutics Ltd - Asset Resilience Ratio
Chimeric Therapeutics Ltd (CHM) has an Asset Resilience Ratio of 26.69% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Chimeric Therapeutics Ltd (CHM) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2022)
This chart shows how Chimeric Therapeutics Ltd's Asset Resilience Ratio has changed over time. See what is Chimeric Therapeutics Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Chimeric Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CHM company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.76 Million | 26.69% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$5.76 Million | 26.69% |
Asset Resilience Insights
- Very High Liquidity: Chimeric Therapeutics Ltd maintains exceptional liquid asset reserves at 26.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Chimeric Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Chimeric Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Chimeric Therapeutics Ltd (2021–2022)
The table below shows the annual Asset Resilience Ratio data for Chimeric Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 52.70% | AU$18.38 Million ≈ $13.01 Million |
AU$34.88 Million ≈ $24.68 Million |
-8.69pp |
| 2021-06-30 | 61.39% | AU$22.41 Million ≈ $15.86 Million |
AU$36.50 Million ≈ $25.83 Million |
-- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more